Adjuvant therapy for high-risk localized breast cancer using weekly adriamycin + daily oral cytoxan with continuous G-CSF [granulocyte colony-stimulating factor] support for 12 weeks followed by weekly abraxane for 12 weeks with concurrent herceptin for women with HER-2/neu positive disease, phase II.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Doxorubicin; Paclitaxel; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 31 Aug 2017 Biomarkers information updated
- 12 Jul 2012 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 10 Apr 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.